Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular af with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score

Journal of the American College of Cardiology

Volumn 65, Issue 14, 2015, Pages 1385-1394

  Lip, Gregory Y H ^a,b   Skjøth, Flemming ^a,c   Rasmussen, Lars Hvilsted ^a   Larsen, Torben Bjerregaard ^a,c  

^a AALBORG UNIVERSITY   (Denmark)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

atrial fibrillation; bleeding; stroke; thromboembolism; warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE HYPERTENSION AGE DIABETES MELLITUS STROKE TRANSIENT ISCHEMIC ATTACK VASCULAR DISESE AGE 65 TO 75 YEARS SEX CATEGORY SCORE; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; NONVALVULAR ATRIAL FIBRILLATION; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; ATRIAL FIBRILLATION; BLOOD CLOTTING; COHORT ANALYSIS; DENMARK; DRUG EFFECTS; ORAL DRUG ADMINISTRATION; REGISTER; STROKE;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; BLOOD COAGULATION; COHORT STUDIES; DENMARK; FEMALE; HUMANS; MALE; REGISTRIES; RISK FACTORS; STROKE;

EID: 84926418687     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.01.044     Document Type: Article

References (27)

1. R.G. Hart, L.A. Pearce, and M.I. Aguilar Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 2007 857 867
2. G.Y. Lip Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why? Eur Heart J 34 2013 1041 1049
3. R. Pisters, D.A. Lane, and F. Marin Stroke and thromboembolism in atrial fibrillation Circ J 76 2012 2289 2304
4. R. De Caterina, S. Husted, and L. Wallentin Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease Thromb Haemost 110 2013 1087 1107
5. P. Gallego, V. Roldan, and F. Marin Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation Thromb Haemost 110 2013 1189 1198
6. S. Husted, R. de Caterina, F. Andreotti for the ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel Thromb Haemost 111 2014 781 782
7. A.J. Camm, G.Y. Lip, and R. De Caterina 2012 Focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation - developed with the special contribution of the European Heart Rhythm Association Europace 14 2012 1385 1413
8. National Institute for Health and Care Excellence. Atrial Fibrillation: The Management of Atrial Fibrillation. NICE Clinical Guideline 180. 2014. Available at: http://www.nice.org.uk/guidance/cg180/resources/guidance-atrial-fibrillation-the-management-of-atrial-fibrillation-pdf. Accessed February 3, 2015.
9. C.T. January, L.S. Wann, and J.S. Alpert 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society J Am Coll Cardiol 64 2014 e1 e76
10. D. Huang, L. Anguo, and W.S. Yue Refinement of ischemic stroke risk in patients with atrial fibrillation and CHA DS -VASc score of 1 Pacing Clin Electrophysiol 37 2014 1442 1447
11. W.A. Ray Evaluating medication effects outside of clinical trials: new-user designs Am J Epidemiol 158 2003 915 920
12. D.E. Singer, Y. Chang, and M.C. Fang The net clinical benefit of warfarin anticoagulation in atrial fibrillation Ann Intern Med 151 2009 297 305
13. A. Banerjee, D.A. Lane, and C. Torp-Pedersen Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study Thromb Haemost 107 2012 584 589
14. J.B. Olesen, G.Y. Lip, and J. Lindhardsen Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a 'real world' nationwide cohort study Thromb Haemost 106 2011 739 749
15. L. Friberg, M. Rosenqvist, and G.Y. Lip Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study Circulation 125 2012 2298 2307
16. M.H. Eckman, D.E. Singer, and J. Rosand Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation Circ Cardiovasc Qual Outcomes 4 2011 14 21
17. J.B. Olesen, C. Torp-Pedersen, and M.L. Hansen The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study Thromb Haemost 107 2012 1172 1179
18. S.J. Connolly, J. Eikelboom, C. Joyner for the AVERROES Steering Committee and Investigators Apixaban in patients with atrial fibrillation N Engl J Med 364 2011 806 817
19. J.J. You, D.E. Singer, and P.A. Howard Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e531S e575S
20. A.C. Skanes, J.S. Healey, and J.A. Cairns Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control Can J Cardiol 28 2012 125 136
21. J.L. Anderson, J.L. Halperin, and N.M. Albert Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines J Am Coll Cardiol 61 2013 1935 1944
22. B.F. Gage, A.D. Waterman, and W. Shannon Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
23. L. Gorin, L. Fauchier, and E. Nonin Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1 Thromb Haemost 103 2010 833 840
24. S. Lahaye, S. Regpala, and S. Lacombe Evaluation of patients' attitudes towards stroke prevention and bleeding risk in atrial fibrillation Thromb Haemost 111 2014 465 473
25. L. Frost, and P. Vestergaard Alcohol and risk of atrial fibrillation or flutter: a cohort study Arch Intern Med 164 2004 1993 1998
26. M. Schmidt, J. Hallas, and S. Friis Potential of prescription registries to capture individual-level use of aspirin and other nonsteroidal anti-inflammatory drugs in Denmark: trends in utilization 1999-2012 Clin Epidemiol 6 2014 155 168
27. D.A. Lane, and G.Y. Lip Patient's values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation Thromb Haemost 111 2014 381 383